{"doi":"10.1016/j.drudis.2018.12.007","title":"Hurdles in gene therapy regulatory approval: a retrospective analysis of European Marketing Authorization Applications","abstract":null,"journal":"Drug Discovery Today","year":2019,"id":26211,"datarank":1.7617992557175386,"base_score":3.4011973816621555,"endowment":3.4011973816621555,"self_citation_contribution":0.5101796072493234,"citation_network_contribution":1.2516196484682152,"self_endowment_contribution":0.5101796072493234,"citer_contribution":1.2516196484682152,"corpus_percentile":null,"corpus_rank":null,"citation_count":29,"citer_count":26,"citers_with_citation_signal":26,"citers_with_endowment":26,"datacite_reuse_total":2,"is_dataset":false,"is_dataset_confidence":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":152166,"name":"Ana Paula Martins","orcid":"0000-0002-3988-1162","position":1,"is_corresponding":false},{"id":152167,"name":"Bruno Sepodes","orcid":null,"position":2,"is_corresponding":false},{"id":152165,"name":"Marta Carvalho","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"base_score":3.4011973816621555,"endowment":3.4011973816621555,"datacite_reuse_total":2,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"30579785","pmcid":null,"openalex_id":"https://openalex.org/W2905722952","authors":[],"funders":[{"funder_name":"Imlygic applied the durable response rate","grant_id":"","title":null}],"total_grants":1,"fwci":1.2273,"citation_percentile":0.83437729,"influential_citations":2,"citation_trend":[{"year":2019,"count":5},{"year":2020,"count":5},{"year":2021,"count":3},{"year":2022,"count":6},{"year":2023,"count":3},{"year":2024,"count":3},{"year":2025,"count":3},{"year":2026,"count":1}],"oa_status":"hybrid","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.1016/j.drudis.2018.12.007","host_type":"journal"},{"url":"https://doi.org/10.1016/j.drudis.2018.12.007","host_type":"HYBRID"},{"url":"https://doi.org/10.1016/j.drudis.2018.12.007","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1359644618304343?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S1359644618304343?httpAccept=text/plain","host_type":"publisher"},{"url":"https://pubmed.ncbi.nlm.nih.gov/30579785","host_type":"repository"}],"fields_of_study":["CAR-T cell therapy research","Biomedical Ethics and Regulation","CRISPR and Genetic Engineering","Medicine","Animals","Europe","Genetic Therapy","Humans","Marketing","Quality Control"],"mesh_terms":["Animals","Europe","Humans","Quality Control","Genetic Therapy","Marketing"],"keywords":["Marketing authorization","Authorization","Postmarketing surveillance","Business","Regulatory science","Medicine","Pharmacology","Marketing","Adverse effect","Bioinformatics","Pathology","Biology"],"sdg_mappings":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.26589306.v1","title":"Additional file 1 of How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.26589306","title":"Additional file 1 of How are health technology assessment bodies responding to the assessment challenges posed by cell and gene therapy?","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-06-08T12:42:49.411315Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}